Spectral Diagnostics Inc. (DIAGF: OTCQX International) |

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Spectral Diagnostics Inc. (DIAGF: OTCQX International) | Spectral Diagnostics announces Proposed Offering of up to $18.2 million Spectral Diagnostics announces Proposed Offering of up to $18.2 million

Spectral Diagnostics announces Proposed Offering of up to $18.2 million

Canada NewsWire

TORONTO , June 11, 2014 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the " Corporation ") today announced it has entered into agreements for a non-brokered private placement of up to $18.2 million (the " Proposed Offering ").

"We are very pleased to have reached agreement with certain of our existing investors for this substantial financing at market, without the need for a price discount or warrants, and with terms fair to all shareholders," stated Anthony Businskas , Executive Vice President and CFO of Spectral. "This financing, and the continued support of our major shareholders, positions us well and gives us great confidence that we should have the necessary funds to successfully complete our EUPHRATES clinical trial," continued Mr. Businskas.

The Corporation intends to use the net proceeds of the Proposed Offering to fund its EUPHRATES clinical development program for PMX, its lead theranostics product for the treatment of severe sepsis with septic shock and for working capital and general corporate purposes.

The Proposed Offering is comprised of a Tranche "A" component and a Tranche "B" component.  The Tranche "A" component is comprised of 45,051,186 common shares of the Corporation (" Shares ") at a subscription price of $0.293 per Share (being the 20 day volume weighted average trading price of the Shares on the TSX for the 20 day period ending June 6, 2014 , the day the Proposed Offering was priced) for aggregate proceeds of $13.2 million , of which (a) 17,064,846 Shares, for aggregate proceeds of $5 million , are proposed to be sold by the Corporation to its lead investor Toray Industries, Inc. (" Toray ") pursuant to a private placement agreement between the Corporation and Toray (the " Toray Private Placement Agreement "); (b) 18,259,382 Shares, for aggregate proceeds of $5.35 million , are proposed to be sold by the Corporation to other insiders pursuant to subscription agreements entered into between the Corporation and such investors; and (c) 9,726,958 Shares, for aggregate proceeds of $2.85  million, are proposed to be sold by the Corporation to other investors pursuant to subscription agreements entered into between the Corporation and such investors.

The Tranche "B" component of the Proposed Offering is comprised of additional Shares to be sold to Toray by the Corporation of up to $5 million , if, as and when the Corporation exercises the right (the " Call Right "), granted by Toray to the Corporation in the Toray Private Placement Agreement, exercisable by written notice given by the Corporation to Toray at any time on or after March 1, 2015 until March 15, 2015 , to require Toray to purchase from the Corporation, at a subsequent closing to occur on April 1, 2015 , up to that number of Shares as is determined by dividing the Call Right amount exercised (up to the $5 million ), as applicable, by the volume weighted average trading price of the Shares on the TSX for the 20 trading days ending on the business day prior to the day the Call Right is exercised.  The Shares to be sold to Toray in Tranche "B" will only be sold if the Corporation exercises the Call Right.

In total, an aggregate of 35,324,228 Shares, for aggregate proceeds of $10,350,000 , are proposed to be sold by the Corporation to insiders in Tranche A of the Proposed Offering.  The number of Shares sold to insiders in Tranche B of the Offering will depend on whether the Corporation exercises the Call Right, and if so, for what amount, and will also depend on the market price of the Shares at the time the Call Right is exercised.

In connection with the Proposed Offering, the board of directors (the " Board ") of the Corporation engaged Koger Valuations Inc. (" Koger ") to consider the fairness of the Proposed Offering.  After the completion of its review and analysis, Koger delivered its opinion to the Board and concluded that the Proposed Offering is fair, from a financial point of view, to the disinterested shareholders of the Corporation, based upon and subject to the various assumptions, limitations, qualifications and other considerations set forth in the fairness opinion.

The Proposed Offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and other approvals, including the approval of the Toronto Stock Exchange.  Given the participation of insiders of the Corporation in the Proposed Offering, the completion of the Proposed Offering is also subject to the approval of disinterested shareholders of the Corporation at a special meeting called for July 22, 2014 (the " Special Meeting ").  The record date for the Special Meeting has been set at June 18, 2014.   Subject to obtaining all of the foregoing approvals, the Proposed Offering is scheduled to close shortly after the Special Meeting.

All shareholders are encouraged to read the management information circular of the Corporation with respect to the Proposed Offering, which is expected to be mailed to shareholders of record on or about June 24, 2014 and will be available on SEDAR at www.sedar.com . The Board has unanimously recommended that shareholders vote FOR the Proposed Offering .  Further details of the Proposed Offering are also contained in the Toray Private Placement Agreement and the other subscription agreements, copies and forms of which have been filed on SEDAR.

Shorecrest Group has been retained as the proxy solicitation agent for the Special Meeting. For questions or assistance, please contact Shorecrest toll-free at 1-888-637-5789, locally at 647-931-7454 or by email at spectral@shorecrestgroup.com .

About Spectral Diagnostics

Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of severe sepsis with septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. Spectral's EUPHRATES trial is the world's only active and most innovative Phase III study in the area of septic shock.

PMX has been approved for therapeutic use in Japan and Europe , and has been used safely and effectively on more than 100,000 patients to date. In March 2009 , Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010 , signed an exclusive distribution agreement for this product in Canada . Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $2 billion market opportunity for Spectral.

Spectral is listed on the Toronto Stock Exchange under the symbol SDI, and on the OTCQX under the symbol DIAGF.  For more information please visit www.spectraldx.com .

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

SOURCE Spectral Diagnostics Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 332

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 199

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 509

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 47

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 19

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 287

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 78

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 241

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading

Top 5 Most Recently Viewed Articles

John T Kim Expands Holdings with $9.65M in Amkor Tech Stock

Updated Category News Views 197

John T Kim Makes Significant Investment in Amkor Tech In a recent SEC filing, substantial insider trading activity was reported, showing that John T Kim, who holds a 10% stake in Amkor Technology Inc. (NASDAQ: AMKR), has acquired shares worth approximately $9.65 million. This key transaction was disclosed in a Form 4 filing, indicating Kim's commitment to the company amid...

Continue Reading
Delcath Systems: Recent Financial Gains and Future Growth Prospects

Updated Category News Views 154

Delcath Systems Secures Significant Funding Delcath Systems, Inc. (NASDAQ:DCTH) is making headlines with the successful exercise of Series E and E1 warrants, bringing in a notable $16.3 million. This funding marks a strategic move for the company, especially following a private placement that took place a few years ago. The timing of this financial boost couldn't be...

Continue Reading
Resolver's Innovative CSAM Detection Service Launch Explained

Updated Category News Views 348

Resolver Launches Pioneering Service for CSAM Detection Resolver, a leading provider of trust and safety intelligence, has introduced an innovative Unknown CSAM Detection Service. This service empowers platforms and services with the capability to identify and classify unknown child sexual abuse material (CSAM) with high precision. Identifying the Challenge in the Digital...

Continue Reading
HanesBrands Finalizes Sale of Champion Business to Authentic Brands

Updated Category News Views 151

HanesBrands Inc. (NYSE: HBI) wrapped up the sale of its global Champion business to Authentic Brands Group, shifting ownership of key intellectual property and assets associated with the brand. Transaction Impact: Simplification or Just Smoke? This deal isn't just another footnote in corporate history; it's a bold stroke by CEO Steve Bratspies who underscored that this...

Continue Reading
NVIDIA's Options Activity: Insights and Market Projections

Updated Category News Views 192

NVIDIA's Options Activity: Insights and Market Projections Financial giants have made a strong bullish move on NVIDIA. An analysis of options history for NVIDIA (NASDAQ: NVDA) revealed a significant number of unusual trades, indicating a growing interest among large-scale investors. As we dig deeper, we find that 45% of traders favor a bullish outlook, while 40% express...

Continue Reading